Although several per- and polyfluoroalkyl substances (PFAS) have been banned or limited in their future use, they continue to have a lasting impact on the environment and human health, with detectable levels apparent in most individuals.
Executives, underwriters, sales leaders, and actuaries are eager to take their underwriting systems to the next level but may face challenges as they explore automated underwriting options. Find out the facts about how a custom AU solution is implemented and scaled w...
Read More
In this insightful Q&A, RGA’s Harvey Brandvein and Nathan Berggoetz from the U.S. Individual Health team share their vision for strengthening protection for middle market long-term care funding needs.
Read More
RGA provides quarterly updates on global product developments, which can be made available upon request.
This issue explores how insurers worldwide are developing products to meet the growing need for mental health solutions.
Read MoreRGA produces a number of specialized publications featuring expert opinion and analysis. Explore our public collection or contact us for whitepapers, webinars, and other resources.
Explore the industry's premier medical underwriting publication.
Explore the ReFlections SeriesInvestigate product development trends and developments from around the world.
Explore the Product Trends SeriesGet the industry's perspective on breaking medical developments.
Explore Global Health Briefs
